BIRMEX

What BIRMEX does

BIRMEX (Laboratorios de Biológicos y Reactivos de México, S.A. de C.V.) is a Mexican state-owned pharmaceutical enterprise wholly owned by the Government of Mexico and founded in 1991 under the Universal Vaccination Program. Its mandate spans the consolidated procurement, importation, distribution, and—in selected categories—domestic manufacturing of vaccines, antivenoms, biologicals, sera, reagents, and essential medicines serving Mexico's public health institutions (IMSS, ISSSTE, IMSS-Bienestar, and the Secretaría de Salud).

The company operates the 'Rutas de la Salud' national distribution network covering over 1,000 routes with approximately 190 trucks, integrated with the Megafarmacia del Bienestar centralized warehouse. It retains direct manufacturing capability for antivenoms (Faboterápicos Polivalentes Antialacrán and Antiviperino, produced since 1930 and 1980 respectively, using proprietary F(ab')2 enzymatic-digestion technology), plus a portfolio of viral, bacterial, and combined vaccines. In February 2026, BIRMEX signed a five-year mRNA vaccine technology transfer agreement with Moderna and Laboratorios Liomont to enable domestic manufacturing of Moderna's COVID-19 vaccine and other respiratory vaccines, alongside joint research on dengue and cancer vaccines.

BIRMEX's business model is a government-mandated procurement consolidator funded through the Mexican federal budget rather than commercial sales. It conducts public tenders and negotiated agreements under the Ley de Adquisiciones framework, optimizing costs through centralized purchasing for the entire national health system. Distribution flows directly from BIRMEX to public clinics and hospitals; there are no commercial retail or export channels. The company also runs academic and research collaborations with IPN and Universidad Rosario Castellanos to develop domestic biopharmaceutical capability, and is positioning itself as Mexico's primary vehicle for pharmaceutical health sovereignty under the current administration.

Name

BIRMEX

Legal name

Laboratorios de Biológicos y Reactivos de México, S.A. de C.V.

Website

https://birmex.gob.mx

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

1–10 employees

Short description

BIRMEX is a Mexican state-owned pharmaceutical enterprise that consolidates procurement, distribution, and select domestic manufacturing of vaccines, antivenoms, and essential medicines for Mexico's public health institutions (IMSS, ISSSTE, IMSS-Bienestar, Secretaría de Salud).

Ownership category

akta.pro rank

Headquarters

HQ city

Mexico City

HQ country

Mexico

HQ region

Latin America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure

Revenue model

1. Procurement Consolidation Services: BIRMEX operates as a government-mandated procurement consolidator for the Mexican public health sector (IMSS, ISSSTE, IMSS-Bienestar, Secretaría de Salud). It conducts public tenders and negotiated agreements to acquire medicines and vaccines, optimizing costs through centralized purchasing. As a state-owned enterprise (SOE), it is funded through the federal budget and does not charge commercial prices for its services.
2. Medical Equipment Investment: MX$11.3 billion in medical equipment investment as part of broader healthcare reform, managed through consolidated procurement processes for the public health sector.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

BIRMEX (Laboratorios de Biológicos y Reactivos de México, S.A. de C.V.) is a Mexican state-owned pharmaceutical company that produces and markets biological products including viral vaccines, bacterial vaccines, combined vaccines, and F(ab')2-type antivenoms (Faboterápicos Polivalentes Antialacrán and Antiviperino). The company also acts as the government-mandated consolidated procurement entity that acquires medicines and biologics on behalf of Mexico's public health institutions and distributes them through the Rutas de la Salud national logistics network.

Product overview

BIRMEX (Laboratorios de Biológicos y Reactivos de México S.A. de C.V.) is a Mexican state-owned pharmaceutical company operating as a single unified entity focused on biologics and pharmaceuticals. Its product portfolio centers on vaccines (viral, bacterial, and combined vaccines), antivenoms (Faboterápicos Polivalentes Antialacrán and Antiviperino since 1930), and related sera and reagents. The company also provides critical services including consolidated medicine procurement for the National Health System and domestic distribution via the 'Rutas de la Salud' program. A major strategic initiative is the five-year mRNA vaccine technology transfer program with Moderna and Laboratorios Liomont to establish domestic manufacturing capacity.

Differentiator

Problem solved

Functional benefit

Products and services

• Faboterápicos Polivalentes Antialacrán (Anti-scorpion antivenom) Antivenom produced by BIRMEX since 1930 against scorpion venom. F(ab')2-type preparation containing specific immunoglobulins modified by enzymatic digestion, lyophilized and albumin-free. Used by Mexico's public health institutions for scorpion envenomation treatment.
• Faboterápicos Polivalentes Antiviperino (Anti-viper antivenom) Antivenom produced since 1980 against snake venom. F(ab')2-type preparation containing specific immunoglobulins modified by enzymatic digestion, lyophilized and albumin-free. Used by Mexico's public health institutions for snake envenomation treatment.
• Viral Vaccines Portfolio Portfolio of viral vaccines including Antirrábica (Rabies), VPH, Rotavirus, Antiamarílica (Yellow Fever), Varicela (Chickenpox), Hepatitis A, Hepatitis B, Sarampión y Rubeola (Measles and Rubella), Triple Viral (MMR), Polio, and Anti-Influenza. Used across Mexico's Universal Vaccination Program.
• Bacterial Vaccines Portfolio Portfolio of bacterial vaccines including DPT, Toxoide Tetánico y Diftérico (Tetanus and Diphtheria Toxoids), BCG, Neumococo, Meningococo, Haemophilus influenzae, Cólera, Tifoidea, and Lisados bacterianos. Used across Mexico's public vaccination and public health programs.
• Combined / Conjugate Vaccines Combined vaccines that protect against multiple diseases in a single dose, supporting Mexico's pediatric and adult immunization programs.
• Consolidated Medicine Procurement (Compras Consolidadas) Government-mandated service that runs public tenders and negotiated procurement agreements to acquire medicines and vaccines on behalf of the Mexican National Health System (IMSS, ISSSTE, IMSS-Bienestar, Secretaría de Salud). Aims to guarantee medicine availability for all Mexicans through centralized purchasing.
• Medicine Distribution (Rutas de la Salud) National distribution service for medicines and biologics using the Rutas de la Salud logistics model, covering over 1,000 routes with approximately 190 trucks serving public health clinics across all Mexican states.
• Vaccines, Sera and Reagents Supply BIRMEX's strategic supply offering as the largest supplier of vaccines, sera and reagents for Mexico's public sector, contributing to public health through disease prevention and treatment measures.

Quantifiable outcome

• Medicine supply across major public health institutions reached above 97%
• +2 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• ModernaflagshipStrategic or Co-development Partner · 10 February 2026Five-year agreement between Mexico's Health Ministry, BIRMEX, Laboratorios Liomont, and U.S.-based Moderna for mRNA vaccine production in Mexico. Includes technology transfer for domestic manufacturing of Moderna's COVID-19 vaccine and other respiratory vaccines. Joint scientific research on vaccines for dengue and cancer. Announced by President Claudia Sheinbaum as part of Mexico's health sovereignty strategy. Moderna CEO Stéphane Bancel stated the collaboration reflects growing vaccine demand in Mexico and supports public health needs while driving the company's geographic diversification.
• Laboratorios LiomontflagshipStrategic or Co-development Partner · 10 February 2026Mexican pharmaceutical firm Liomont is a co-signatory in the five-year mRNA vaccine production agreement alongside BIRMEX, Mexico's Health Ministry, and Moderna. Liomont serves as the domestic manufacturing partner for the technology transfer, contributing local pharmaceutical production expertise and facilities.
• Instituto Politécnico Nacional (IPN)coreStrategic or Co-development PartnerCollaboration agreement signed between IPN and BIRMEX for joint initiatives in scientific research, technological development, and training related to biological products and public health. The partnership strengthens academic-industry ties in Mexico's pharmaceutical sector.
• Universidad Rosario CastellanoscoreStrategic or Co-development PartnerCollaboration agreement signed between Universidad Rosario Castellanos and BIRMEX for scientific research, technology development, and human capital formation in the biologics and public health domain.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Instituto Butantan: Brazilian state-owned biologics manufacturer and public-sector vaccine/serum producer. Direct peer because it mirrors BIRMEX's mandate of producing immunobiologicals and supplying national public health programs, with similar antivenom expertise.
• Laboratorios de Biológicos y Reactivos (BIRMEX) Rival Federal Entities in Mexico: Mexico's Secretaría de Salud and IMSS-Bienestar collectively act as both customer and counterparties; comparable in distributing medicines and biologics to public-sector clients under consolidated procurement frameworks.
• Bio-Manguinhos / Fiocruz: Brazilian federal immunobiologicals producer under the Fiocruz umbrella. Direct peer in manufacturing vaccines and biologics for the Brazilian public health system with technology-transfer arrangements (e.g., AstraZeneca).
• Laboratorios Liomont: Mexican pharmaceutical firm and BIRMEX's co-signatory in the Moderna mRNA technology-transfer consortium. Direct peer in Mexican domestic manufacturing of vaccines and biologics for the public sector.
• INSABI / IMSS-Bienestar: Mexican public health entity responsible for delivering medical services to uninsured populations. Direct institutional counterpart that both consumes BIRMEX's procurement output and influences health policy in Mexico.

Broad incumbents

• Serum Institute of India: World's largest vaccine manufacturer with a deep public-sector, government-anchored mandate for India. Broad incumbent comparable in scale of biologicals output and dependence on national immunization programs.
• Sanofi Pasteur: Global vaccine manufacturer with established mRNA and influenza capabilities. Broad incumbent relevant as a multinational supplier that competes in tenders BIRMEX consolidates and as a technology-transfer counterparty type.
• CSL Seqirus: Global antivenom and biologics manufacturer with overlapping antivenom, vaccine, and plasma-derivative capabilities. Broad incumbent peer for BIRMEX's Faboterápicos and sera portfolio.

Regional players

• Sinergium Biotech: Argentine biologics manufacturer producing vaccines, antivenoms, and recombinant proteins. Regional peer with overlapping antivenom portfolio and Latin American public-sector clients.

Others

• Moderna: Strategic partner of BIRMEX in the five-year mRNA technology-transfer agreement. Listed as an ecosystem partner rather than a competitor; central to BIRMEX's biologics and mRNA pipeline trajectory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/birmex
• Facebookfacebook.com/BIRMEXLabs
• Instagraminstagram.com/birmex_mx
• LinkedInlinkedin.com/company/birmex

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIRMEX